Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV pantoprazole pharmacokinetics study in hospitalized pediatric patients with GERD or candidates for acid suppression
2014-002182-29Phase 4Terminated
- Sponsor
- Pfizer
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of pantoprazole in gastroesophageal reflux disease (GERD) (2 cohorts), sponsored by Pfizer. Primary endpoints: Day 1 Tmax of pantoprazole, Day 1 Cmax of pantoprazole and 5 more. Started Feb 2016; status: terminated.
02
Drugs
pantoprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2014-002182-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002182-29.